IBT is pioneering the development of the first multivalent toxoid-based vaccine against Staphylococcus aureus as well as immunotherapies for several viral diseases.
ROCKVILLE, MD. SEPTEMBER 14, 2020
Integrated BioTherapeutics Inc. (IBT), a Maryland company specializing in emerging infectious diseases, announced today Dr. Gary Nabors has joined the firm as Executive Vice President and Chief Development Officer. IBT is a biotechnology company focused on the development of vaccines and immunotherapeutics.
“We are pleased to welcome Dr. Nabors to the IBT team. His extensive experience in advanced development of infectious diseases products will bring great value to IBT’s efforts to transition its lead product candidates into the clinic,” said Dr. M. Javad Aman, President of IBT. “Dr. Nabors’ role as head of product development will enable IBT to effectively translate its discovery pipeline into practical solutions for infectious diseases.”
Prior to joining IBT, Dr. Nabors served in leading roles at several companies including Sanofi Pasteur, Antex Biologics, Emergent BioSolutions, and DynPort Vaccine Company (DVC). He provided strategic leadership as President of DVC from 2014 through 2020. Prior to that, Dr. Nabors oversaw the characterization of biological threat agents as the Deputy Director of the National Biological Threat Characterization Center from 2012-2014. Dr. Nabors also held positions of increasing responsibility in R&D at Emergent BioSolutions from 2003-2012, where he managed a portfolio of products as Senior Vice President of Vaccines and Therapeutics.
“I’ve had the privilege of getting to know the IBT team through past collaborations and I am excited to join the management team to help advance their breakthrough products into clinical development,” said Dr. Nabors. “I look forward to supporting IBT’s mission to bring novel drugs and therapeutics to market to address the public health threat from emerging and re-emerging infectious diseases.”
About Integrated BioTherapeutics:
IBT is developing vaccines and immunotherapies for several bacterial and viral infections. IBT’s lead vaccine product is a first-in-class multi-component toxoid vaccine (IBT-V02) against Staphylococcus aureus. Supported by CARB-X and Novo Holding’s Repair Impact Fund, IBT-V02 is currently undergoing cGMP manufacturing and IND-enabling studies with initiation of clinical trials anticipated in late 2021. IBT’s immunotherapeutic pipeline includes a cocktail of monoclonal antibodies for treatment of hemorrhagic fever caused by ebolaviruses (IBT-T02) and a potent, first-in-class, monoclonal antibody against marburgviruses. Furthermore, IBT is developing a number of product candidates for S. aureus, anthrax, and C. difficile based on its proprietary Infection Site Targeted Anti-toxin Antibody (ISTAb) technology. Learn more about IBT’s pipeline at https://www.integratedbiotherapeutics.com.
IBT Bioservices, the contract research division of IBT, offers in-vitro assays and animal infection models to enable lead-to-candidate selection and eventual progress to IND and clinical development.
To learn more visit http://www.IBTBioServices.com or email us at Services@IBTBioservices.com.